{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T20:46:06Z","timestamp":1774471566463,"version":"3.50.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T00:00:00Z","timestamp":1714176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T00:00:00Z","timestamp":1714176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40273-024-01377-9","type":"journal-article","created":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T06:02:51Z","timestamp":1714197771000},"page":"737-749","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Advances in Addressing Patient Heterogeneity in Economic Evaluation: A Review of the Methods Literature"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4869-7524","authenticated-orcid":false,"given":"Gemma E.","family":"Shields","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0778-312X","authenticated-orcid":false,"given":"Paul","family":"Clarkson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7091-0972","authenticated-orcid":false,"given":"Ash","family":"Bullement","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8844-4746","authenticated-orcid":false,"given":"Warren","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6977-4483","authenticated-orcid":false,"given":"Mark","family":"Wilberforce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1968-6378","authenticated-orcid":false,"given":"Tracey","family":"Farragher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7950-2649","authenticated-orcid":false,"given":"Arpana","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8801-3559","authenticated-orcid":false,"given":"Linda M.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,27]]},"reference":[{"key":"1377_CR1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40273-012-0015-4","volume":"31","author":"JPC Grutters","year":"2013","unstructured":"Grutters JPC, Sculpher M, Briggs AH, Severens JL, Candel MJ, Stahl JE, De Ruysscher D, Boer A, Ramaekers BLT, Joore MA. Acknowledging patient heterogeneity in economic evaluation. Pharmacoeconomics. 2013;31:111\u201323. https:\/\/doi.org\/10.1007\/s40273-012-0015-4.","journal-title":"Pharmacoeconomics"},{"key":"1377_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"A Briggs","year":"2006","unstructured":"Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006."},{"key":"1377_CR3","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/J.JVAL.2013.02.013","volume":"16","author":"BLT Ramaekers","year":"2013","unstructured":"Ramaekers BLT, Joore MA, Grutters JPC. How should we deal with patient heterogeneity in economic evaluation: a systematic review of national pharmacoeconomic guidelines. Value Health. 2013;16:855\u201362. https:\/\/doi.org\/10.1016\/J.JVAL.2013.02.013.","journal-title":"Value Health"},{"key":"1377_CR4","doi-asserted-by":"crossref","unstructured":"Espinoza MA, Sculpher MJ, Manca A, Basu A. Analysing heterogeneity to support decision making. In: Encyclopedia of Health Economics. Elsevier; 2004. p. 71\u20136.","DOI":"10.1016\/B978-0-12-375678-7.01420-6"},{"key":"1377_CR5","volume-title":"Developing a protocol for observational comparative effectiveness research: a user\u2019s guide","author":"R Varadhan","year":"2013","unstructured":"Varadhan R, Seeger JD, et al. Estimation and reporting of heterogeneity of treatment effects. In: Velentgas P, Dreyer NA, Nourjah P, et al., editors. Developing a protocol for observational comparative effectiveness research: a user\u2019s guide. Rockville: Agency for Healthcare Research and Quality; 2013."},{"key":"1377_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12874-017-0466-6\/TABLES\/5","volume":"18","author":"M Dahan","year":"2018","unstructured":"Dahan M, Scemama C, Porcher R, Biau DJ. Reporting of heterogeneity of treatment effect in cohort studies: a review of the literature. BMC Med Res Methodol. 2018;18:1\u201311. https:\/\/doi.org\/10.1186\/S12874-017-0466-6\/TABLES\/5.","journal-title":"BMC Med Res Methodol"},{"key":"1377_CR7","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1177\/0272989X14538705","volume":"34","author":"MA Espinoza","year":"2014","unstructured":"Espinoza MA, Manca A, Claxton K, Sculpher MJ. The value of heterogeneity for cost-effectiveness subgroup analysis: conceptual framework and application. Med Decis Mak. 2014;34:951\u201364. https:\/\/doi.org\/10.1177\/0272989X14538705.","journal-title":"Med Decis Mak"},{"key":"1377_CR8","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1136\/bmj.318.7197.1551","volume":"318","author":"S Palmer","year":"1999","unstructured":"Palmer S, Raftery J. Opportunity cost. BMJ. 1999;318:1551. https:\/\/doi.org\/10.1136\/bmj.318.7197.1551.","journal-title":"BMJ"},{"issue":"11","key":"1377_CR9","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1001\/jama.2016.11237","volume":"25","author":"A Basu","year":"2019","unstructured":"Basu A, Grieve R, Pritchard D, Stevens W. One size does not always fit all in value assessment. Am J Manag Care. 2019;25(11):540\u20132. https:\/\/doi.org\/10.1001\/jama.2016.11237.","journal-title":"Am J Manag Care"},{"key":"1377_CR10","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2165\/11584630-000000000-00000","volume":"29","author":"R Jain","year":"2011","unstructured":"Jain R, Grabner M, Onukwugha E. Sensitivity analysis in cost-effectiveness studies: from guidelines to practice. Pharmacoeconomics. 2011;29:297\u2013314. https:\/\/doi.org\/10.2165\/11584630-000000000-00000.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1377_CR11","first-page":"3","volume":"2","author":"B Ramaekers","year":"2014","unstructured":"Ramaekers B, Grutters JJM. Acknowledging patient heterogeneity in health technology assessment. OA Epidemiol. 2014;2(1):3.","journal-title":"OA Epidemiol"},{"key":"1377_CR12","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1177\/0272989X17746989","volume":"38","author":"TA Lavelle","year":"2018","unstructured":"Lavelle TA, Kent DM, Lundquist CM, Thorat T, Cohen JT, Wong JB, Olchanski N, Neumann PJ. Patient variability seldom assessed in cost-effectiveness studies. Med Decis Making. 2018;38:487\u201394. https:\/\/doi.org\/10.1177\/0272989X17746989.","journal-title":"Med Decis Making"},{"key":"1377_CR13","first-page":"540","volume":"25","author":"A Basu","year":"2019","unstructured":"Basu A, Grieve R, Pritchard D, Stevens W. One size does not always fit all in value assessment. Am J Manag Care. 2019;25:540\u20132.","journal-title":"Am J Manag Care"},{"key":"1377_CR14","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jval.2018.10.006","volume":"22","author":"RD Watts","year":"2019","unstructured":"Watts RD, Li IW. Use of checklists in reviews of health economic evaluations, 2010 to 2018. Value Health. 2019;22:377\u201382. https:\/\/doi.org\/10.1016\/j.jval.2018.10.006.","journal-title":"Value Health"},{"key":"1377_CR15","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1136\/bmj.313.7052.275","volume":"313","author":"MF Drummond","year":"1996","unstructured":"Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. Br Med J. 1996;313:275\u201383.","journal-title":"Br Med J"},{"key":"1377_CR16","volume-title":"Methods for the economic evaluation of health care programmes","author":"M Drummond","year":"2015","unstructured":"Drummond M, Schulpher M, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 4th ed. Oxford: Oxford University Press; 2015.","edition":"4"},{"key":"1377_CR17","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1017\/s0266462305050324","volume":"21","author":"S Evers","year":"2005","unstructured":"Evers S, Goossens M, de Vet H, van Tulder M, Ament A. Criteria list for assessment of methodological quality of economic evaluations: consensus on health economic criteria. Int J Technol Assess Health Care. 2005;21:240\u20135. https:\/\/doi.org\/10.1017\/s0266462305050324.","journal-title":"Int J Technol Assess Health Care"},{"key":"1377_CR18","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2165\/00019053-200624040-00006","volume":"24","author":"Z Philips","year":"2006","unstructured":"Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics. 2006;24:355\u201371.","journal-title":"Pharmacoeconomics"},{"key":"1377_CR19","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40273-015-0327-2","volume":"34","author":"P Vemer","year":"2016","unstructured":"Vemer P, Corro Ramos I, van Voorn GAK, Al MJ, Feenstra TL. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. Pharmacoeconomics. 2016;34:349\u201361. https:\/\/doi.org\/10.1007\/s40273-015-0327-2.","journal-title":"Pharmacoeconomics"},{"key":"1377_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/00005650-200301000-00007","volume":"41","author":"CF Chiou","year":"2003","unstructured":"Chiou CF, Hay JW, Wallace JF, Bloom BS, Neumann PJ, Sullivan SD, Yu HT, Keeler EB, Henning JM, Ofman JJ. Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care. 2003;41:32\u201344. https:\/\/doi.org\/10.1097\/00005650-200301000-00007.","journal-title":"Med Care"},{"key":"1377_CR21","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/hec.592","volume":"10","author":"M Sculpher","year":"2001","unstructured":"Sculpher M, Gafni A. Recognizing diversity in public preferences: the use of preference sub-groups in cost-effectiveness analysis. Health Econ. 2001;10:317\u201324. https:\/\/doi.org\/10.1002\/hec.592.","journal-title":"Health Econ"},{"key":"1377_CR22","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1177\/0272989X03256883","volume":"23","author":"GS Zaric","year":"2003","unstructured":"Zaric GS. The impact of ignoring population heterogeneity when Markov models are used in cost-effectiveness analysis. Med Decis Making. 2003;23:379\u201396. https:\/\/doi.org\/10.1177\/0272989X03256883.","journal-title":"Med Decis Making"},{"key":"1377_CR23","doi-asserted-by":"publisher","first-page":"3687","DOI":"10.1002\/SIM.1586","volume":"22","author":"DJ Spiegelhalter","year":"2003","unstructured":"Spiegelhalter DJ, Best NG. Bayesian approaches to multiple sources of evidence and uncertainty in complex cost-effectiveness modelling. Stat Med. 2003;22:3687\u2013709. https:\/\/doi.org\/10.1002\/SIM.1586.","journal-title":"Stat Med"},{"key":"1377_CR24","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/hec.1148","volume":"15","author":"A Brennan","year":"2006","unstructured":"Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ. 2006;15:1295\u2013310. https:\/\/doi.org\/10.1002\/hec.1148.","journal-title":"Health Econ"},{"issue":"8","key":"1377_CR25","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2165\/00019053-200826080-00002","volume":"26","author":"BMS Heeg","year":"2008","unstructured":"Heeg BMS, Damen J, Buskens E, Caleo S, De Charro F, Van Hout BA. Modelling approaches: the case of schizophrenia. Pharmacoeconomics. 2008;26(8):633\u201348. https:\/\/doi.org\/10.2165\/00019053-200826080-00002.","journal-title":"Pharmacoeconomics"},{"key":"1377_CR26","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/hec.678","volume":"11","author":"JS Hoch","year":"2002","unstructured":"Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ. 2002;11:415\u201330. https:\/\/doi.org\/10.1002\/hec.678.","journal-title":"Health Econ"},{"key":"1377_CR27","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1002\/hec.843","volume":"13","author":"AR Willan","year":"2004","unstructured":"Willan AR, Briggs AH, Hoch JS. Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. Health Econ. 2004;13:461\u201375. https:\/\/doi.org\/10.1002\/hec.843.","journal-title":"Health Econ"},{"key":"1377_CR28","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/hec.1008","volume":"14","author":"RM Nixon","year":"2005","unstructured":"Nixon RM, Thompson SG. Methods for incorporating covariate adjustment, subgroup analysis and between-centre differences into cost-effectiveness evaluations. Health Econ. 2005;14:1217\u201329. https:\/\/doi.org\/10.1002\/hec.1008.","journal-title":"Health Econ"},{"key":"1377_CR29","unstructured":"Drummond M. Methods for the economic evaluation of health care programmes. 3rd ed. New York: Oxford University Press; 2005."},{"key":"1377_CR30","doi-asserted-by":"publisher","first-page":"807","DOI":"10.2165\/00019053-200725100-00001","volume":"25","author":"JS Hoch","year":"2007","unstructured":"Hoch JS, Dewa CS. Lessons from trial-based cost-effectiveness analyses of mental health interventions: why uncertainty about the outcome, estimate and willingness to pay matters. Pharmacoeconomics. 2007;25:807\u201316. https:\/\/doi.org\/10.2165\/00019053-200725100-00001.","journal-title":"Pharmacoeconomics"},{"key":"1377_CR31","doi-asserted-by":"publisher","unstructured":"Marshall DA, Hux M.  Design and analysis issues for economic analysis alongside clinical trials. Med Care 2009;47(7 Suppl 1):S14\u201320. https:\/\/doi.org\/10.1097\/MLR.0b013e3181a31971.","DOI":"10.1097\/MLR.0b013e3181a31971"},{"key":"1377_CR32","volume-title":"Economic evaluation in clinical trials","author":"HA Glick","year":"2007","unstructured":"Glick HA, Doshi JA, Sonnad SS, Polsky D. Economic evaluation in clinical trials. Oxford: Oxford University Press; 2007."},{"key":"1377_CR33","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/hec.788","volume":"12","author":"D Coyle","year":"2003","unstructured":"Coyle D, Buxton MJ, O\u2019Brien BJ. Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria. Health Econ. 2003;12:421\u20137. https:\/\/doi.org\/10.1002\/hec.788.","journal-title":"Health Econ"},{"key":"1377_CR34","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1177\/0272989X06297393","volume":"27","author":"A Basu","year":"2007","unstructured":"Basu A, Meltzer D. Value of information on preference heterogeneity and individualized care. Med Decis Mak. 2007;27:112\u201327. https:\/\/doi.org\/10.1177\/0272989X06297393.","journal-title":"Med Decis Mak"},{"key":"1377_CR35","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2165\/00019053-200826090-00009","volume":"26","author":"M Sculpher","year":"2008","unstructured":"Sculpher M. Subgroups and heterogeneity in cost-effectiveness analysis. Pharmacoeconomics. 2008;26:799\u2013806.","journal-title":"Pharmacoeconomics"},{"key":"1377_CR36","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/J.JVAL.2022.03.022","volume":"25","author":"WV Padula","year":"2022","unstructured":"Padula WV, Kreif N, Vanness DJ, Adamson B, Rueda JD, Felizzi F, Jonsson P, IJzerman MJ, Butte A, Crown W. Machine learning methods in health economics and outcomes research\u2014the PALISADE checklist: a good practices report of an ISPOR task force. Value Health. 2022;25:1063\u201380. https:\/\/doi.org\/10.1016\/J.JVAL.2022.03.022.","journal-title":"Value Health"},{"key":"1377_CR37","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jval.2022.04.1738","volume":"26","author":"EM Oehrlein","year":"2023","unstructured":"Oehrlein EM, Schoch S, Burcu M, McBeth JF, Bright J, Pashos CL, Willke R, Love TR, Mattingly TJ, Perfetto EM. Developing patient-centered real-world evidence: emerging methods recommendations from a consensus process. Value Health. 2023;26:28\u201338. https:\/\/doi.org\/10.1016\/j.jval.2022.04.1738.","journal-title":"Value Health"},{"key":"1377_CR38","doi-asserted-by":"publisher","DOI":"10.1515\/fhep-2019-0013","author":"DL Veenstra","year":"2020","unstructured":"Veenstra DL, Mandelblatt J, Neumann P, Basu A, Peterson JF, Ramsey SD. Health economics tools and precision medicine: opportunities and challenges. Forum Health Econ Policy. 2020. https:\/\/doi.org\/10.1515\/fhep-2019-0013.","journal-title":"Forum Health Econ Policy"},{"key":"1377_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/23808993.2018.1421858","volume":"3","author":"SP Gavan","year":"2018","unstructured":"Gavan SP, Thompson AJ, Payne K. The economic case for precision medicine. Expert Rev Precis Med Drug Dev. 2018;3:1\u20139. https:\/\/doi.org\/10.1080\/23808993.2018.1421858.","journal-title":"Expert Rev Precis Med Drug Dev"},{"key":"1377_CR40","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1377\/hlthaff.2017.1624","volume":"37","author":"GS Ginsburg","year":"2018","unstructured":"Ginsburg GS, Phillips KA. Precision medicine: from science to value. Health Aff. 2018;37:694\u2013701. https:\/\/doi.org\/10.1377\/hlthaff.2017.1624.","journal-title":"Health Aff"},{"key":"1377_CR41","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/S40273-022-01176-0","volume":"40","author":"RE Pataky","year":"2022","unstructured":"Pataky RE, Bryan S, Sadatsafavi M, Peacock S, Regier DA. Tools for the economic evaluation of precision medicine: a scoping review of frameworks for valuing heterogeneity-informed decisions. Pharmacoeconomics. 2022;40:931\u201341. https:\/\/doi.org\/10.1007\/S40273-022-01176-0.","journal-title":"Pharmacoeconomics"},{"key":"1377_CR42","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1177\/0272989X12458348","volume":"32","author":"AH Briggs","year":"2012","unstructured":"Briggs AH, Weinstein MC, Fenwick EAL, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making. 2012;32:722\u201332. https:\/\/doi.org\/10.1177\/0272989X12458348.","journal-title":"Med Decis Making"},{"key":"1377_CR43","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1177\/0272989X19881654.","volume":"39","author":"A Alshreef","year":"2019","unstructured":"Alshreef A, Latimer N, Tappenden P, Wong R, Hughes D, Fotheringham J, Dixon S. Statistical methods for adjusting estimates of treatment effectiveness for patient nonadherence in the context of time-to-event outcomes and health technology assessment: a systematic review of methodological papers. Med Decis Mak. 2019;39:910\u201325. https:\/\/doi.org\/10.1177\/0272989X19881654.","journal-title":"Med Decis Mak"},{"key":"1377_CR44","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1177\/0272989X15574500","volume":"36","author":"ML Bongers","year":"2016","unstructured":"Bongers ML, De Ruysscher D, Oberije C, Lambin P, Uyl-De Groot CA, Coup\u00e9 VMH. Multistate statistical modeling: A tool to build a lung cancer microsimulation model that includes parameter uncertainty and patient heterogeneity. Med Decis Mak. 2016;36:86\u2013100. https:\/\/doi.org\/10.1177\/0272989X15574500.","journal-title":"Med Decis Mak"},{"key":"1377_CR45","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/S40273-015-0273-Z","volume":"33","author":"EH Elbasha","year":"2015","unstructured":"Elbasha EH, Chhatwal J. Characterizing heterogeneity bias in cohort-based models. Pharmacoeconomics. 2015;33:857\u201365. https:\/\/doi.org\/10.1007\/S40273-015-0273-Z.","journal-title":"Pharmacoeconomics"},{"key":"1377_CR46","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/0272989X20980327","volume":"41","author":"P Murphy","year":"2021","unstructured":"Murphy P, Claxton L, Hodgson R, Glynn D, Beresford L, Walton M, Llewellyn A, Palmer S, Dias S. Exploring heterogeneity in histology-independent technologies and the implications for cost-effectiveness. Med Decis Making. 2021;41:165\u201378. https:\/\/doi.org\/10.1177\/0272989X20980327.","journal-title":"Med Decis Making"},{"key":"1377_CR47","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1177\/0272989X12453503","volume":"33","author":"JF O\u2019Mahony","year":"2013","unstructured":"O\u2019Mahony JF, Van Rosmalen J, Zauber AG, Van Ballegooijen M. Multicohort models in cost-effectiveness analysis: why aggregating estimates over multiple cohorts can hide useful information. Med Decis Making. 2013;33:407\u201314. https:\/\/doi.org\/10.1177\/0272989X12453503.","journal-title":"Med Decis Making"},{"key":"1377_CR48","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/S40258-019-00462-X","volume":"17","author":"P Saramago","year":"2019","unstructured":"Saramago P, Espinoza MA, Sutton AJ, Manca A, Claxton K. The value of further research: the added value of individual-participant level data. Appl Health Econ Health Policy. 2019;17:273\u201384. https:\/\/doi.org\/10.1007\/S40258-019-00462-X.","journal-title":"Appl Health Econ Health Policy"},{"key":"1377_CR49","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1177\/0272989X14550499","volume":"34","author":"P Vemer","year":"2014","unstructured":"Vemer P, Goossens LMA, Rutten-van M\u00f6lken MPMH. Not simply more of the same: distinguishing between patient heterogeneity and parameter uncertainty. Med Decis Mak. 2014;34:1048\u201358. https:\/\/doi.org\/10.1177\/0272989X14550499.","journal-title":"Med Decis Mak"},{"key":"1377_CR50","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1177\/0272989X15570113","volume":"35","author":"NJ Welton","year":"2015","unstructured":"Welton NJ, Soares MO, Palmer S, Ades AE, Harrison D, Shankar-Hari M, Rowan KM. Accounting for heterogeneity in relative treatment effects for use in cost-effectiveness models and value-of-information analyses. Med Decis Mak. 2015;35:608\u201321. https:\/\/doi.org\/10.1177\/0272989X15570113.","journal-title":"Med Decis Mak"},{"key":"1377_CR51","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1002\/HEC.4263","volume":"30","author":"C Bonander","year":"2021","unstructured":"Bonander C, Svensson M. Using causal forests to assess heterogeneity in cost-effectiveness analysis. Health Econ. 2021;30:1818\u201332. https:\/\/doi.org\/10.1002\/HEC.4263.","journal-title":"Health Econ"},{"key":"1377_CR52","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s10198-018-1013-z","volume":"20","author":"Q Cao","year":"2019","unstructured":"Cao Q, Buskens E, Hillege HL, Jaarsma T, Postma M, Postmus D. Stratified treatment recommendation or one-size-fits-all? A health economic insight based on graphical exploration. Eur J Health Econ. 2019;20:475\u201382. https:\/\/doi.org\/10.1007\/s10198-018-1013-z.","journal-title":"Eur J Health Econ"},{"key":"1377_CR53","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1177\/0272989X221100799","volume":"42","author":"S Moler-Zapata","year":"2022","unstructured":"Moler-Zapata S, Grieve R, Lugo-Palacios D, Hutchings A, Silverwood R, Keele L, Kircheis T, Cromwell D, Smart N, Hinchliffe R, O\u2019Neill S. Local instrumental variable methods to address confounding and heterogeneity when using electronic health records: an application to emergency surgery. Med Decis Making. 2022;42:1010\u201326. https:\/\/doi.org\/10.1177\/0272989X221100799.","journal-title":"Med Decis Making"},{"key":"1377_CR54","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/J.JVAL.2012.04.007","volume":"15","author":"TM Benning","year":"2012","unstructured":"Benning TM, Kimman ML, Dirksen CD, Boersma LJ, Dellaert BGC. Combining individual-level discrete choice experiment estimates and costs to inform health care management decisions about customized care: the case of follow-up strategies after breast cancer treatment. Value Health. 2012;15:680\u20139. https:\/\/doi.org\/10.1016\/J.JVAL.2012.04.007.","journal-title":"Value Health"},{"key":"1377_CR55","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/S40273-017-0505-5","volume":"35","author":"D Goto","year":"2017","unstructured":"Goto D, Shih YCT, Lecomte P, Olson M, Udeze C, Park Y, Mullins CD. Regression-based approaches to patient-centered cost-effectiveness analysis. Pharmacoeconomics. 2017;35:685\u201395. https:\/\/doi.org\/10.1007\/S40273-017-0505-5.","journal-title":"Pharmacoeconomics"},{"key":"1377_CR56","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1177\/0272989X17702379","volume":"37","author":"DD Kim","year":"2017","unstructured":"Kim DD, Basu A. New metrics for economic evaluation in the presence of heterogeneity: focusing on evaluating policy alternatives rather than treatment alternatives. Med Decis Making. 2017;37:930\u201341. https:\/\/doi.org\/10.1177\/0272989X17702379.","journal-title":"Med Decis Making"},{"key":"1377_CR57","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/J.JVAL.2011.07.015","volume":"15","author":"A Van Gestel","year":"2012","unstructured":"Van Gestel A, Grutters J, Schouten J, Webers C, Beckers H, Joore M, Severens J. The role of the expected value of individualized care in cost-effectiveness analyses and decision making. Value Health. 2012;15:13\u201321. https:\/\/doi.org\/10.1016\/J.JVAL.2011.07.015.","journal-title":"Value Health"},{"key":"1377_CR58","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1177\/09622802221115876","volume":"31","author":"Y Xu","year":"2022","unstructured":"Xu Y, Greene TH, Bress AP, Bellows BK, Zhang Y, Zhang Z, Kolm P, Weintraub WS, Moran AS, Shen J. An efficient approach for optimizing the cost-effective individualized treatment rule using conditional random forest. Stat Methods Med Res. 2022;31:2122\u201336. https:\/\/doi.org\/10.1177\/09622802221115876.","journal-title":"Stat Methods Med Res"},{"key":"1377_CR59","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1080\/01621459.2017.1319839","volume":"113","author":"S Wager","year":"2018","unstructured":"Wager S, Athey S. Estimation and inference of heterogeneous treatment effects using random forests. J Am Stat Assoc. 2018;113:1228\u201342. https:\/\/doi.org\/10.1080\/01621459.2017.1319839.","journal-title":"J Am Stat Assoc"},{"key":"1377_CR60","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1002\/HEC.1291","volume":"16","author":"A Basu","year":"2007","unstructured":"Basu A, Heckman JJ, Navarro-Lozano S, Urzua S. Use of instrumental variables in the presence of heterogeneity and self-selection: an application to treatments of breast cancer patients. Health Econ. 2007;16:1133\u201357. https:\/\/doi.org\/10.1002\/HEC.1291.","journal-title":"Health Econ"},{"key":"1377_CR61","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/JAE.2343","volume":"29","author":"A Basu","year":"2014","unstructured":"Basu A. Estimating Person-centered Treatment (PeT) effects using instrumental variables: an application to evaluating prostate cancer treatments. J Appl Econom (Chichester, England). 2014;29:671. https:\/\/doi.org\/10.1002\/JAE.2343.","journal-title":"J Appl Econom (Chichester, England)."},{"key":"1377_CR62","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/S40273-014-0183-5\/METRICS","volume":"32","author":"JJ Caro","year":"2014","unstructured":"Caro JJ, M\u00f6ller J. Decision-analytic models: current methodological challenges. Pharmacoeconomics. 2014;32:943\u201350. https:\/\/doi.org\/10.1007\/S40273-014-0183-5\/METRICS.","journal-title":"Pharmacoeconomics"},{"key":"1377_CR63","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/S40273-021-01108-4","volume":"40","author":"GE Shields","year":"2022","unstructured":"Shields GE, Wilberforce M, Clarkson P, Farragher T, Verma A, Davies LM. Factors limiting subgroup analysis in cost-effectiveness analysis and a call for transparency. Pharmacoeconomics. 2022;40:149\u201356. https:\/\/doi.org\/10.1007\/S40273-021-01108-4.","journal-title":"Pharmacoeconomics"},{"key":"1377_CR64","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40273-018-0734-2","volume":"37","author":"V Soekhai","year":"2019","unstructured":"Soekhai V, de Bekker-Grob EW, Ellis AR, Vass CM. Discrete choice experiments in health economics: past, present and future. Pharmacoeconomics. 2019;37:201\u201326. https:\/\/doi.org\/10.1007\/s40273-018-0734-2.","journal-title":"Pharmacoeconomics"},{"key":"1377_CR65","doi-asserted-by":"publisher","DOI":"10.3390\/IJERPH191610159","author":"F Schad","year":"2022","unstructured":"Schad F, Thronicke A. Real-World Evidence\u2014Current Developments and Perspectives. Int J Environ Res Public Health. 2022. https:\/\/doi.org\/10.3390\/IJERPH191610159.","journal-title":"Int J Environ Res Public Health"},{"key":"1377_CR66","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1517\/IJHPM.2019.119","volume":"9","author":"J Love-Koh","year":"2020","unstructured":"Love-Koh J. How useful are early economic models?: Comment on \u201cProblems and promises of health technologies: the role of early health economic modelling.\u201d Int J Health Policy Manag. 2020;9:215. https:\/\/doi.org\/10.1517\/IJHPM.2019.119.","journal-title":"Int J Health Policy Manag"},{"key":"1377_CR67","doi-asserted-by":"publisher","DOI":"10.3390\/IJERPH17041171","author":"E Parody-r\u00faa","year":"2020","unstructured":"Parody-r\u00faa E, Rubio-valera M, Guevara-cuellar C, G\u00f3mez-lumbreras A, Casajuana-closas M, Carbonell-duacastella C, Aznar-lou I. Economic evaluations informed exclusively by real world data: a systematic review. Int J Environ Res Public Health. 2020. https:\/\/doi.org\/10.3390\/IJERPH17041171.","journal-title":"Int J Environ Res Public Health"},{"key":"1377_CR68","doi-asserted-by":"publisher","DOI":"10.1201\/9781315188850","volume-title":"Bayesian cost-effectiveness analysis of medical treatments","author":"E Moreno","year":"2019","unstructured":"Moreno E, Vazquez-Polo FJ, Negr\u00edn-Hern\u00e1ndez MA. Bayesian cost-effectiveness analysis of medical treatments. CRC Press; 2019."},{"issue":"12 Suppl","key":"1377_CR69","doi-asserted-by":"publisher","first-page":"S469","DOI":"10.1016\/j.jval.2023.09.2546","volume":"26","author":"N Hawkins","year":"2023","unstructured":"Hawkins N, Szabo S. PCR107 (How) should cost-effectiveness analysis accommodate heterogeneity in patient preferences? Value Health. 2023;26(12 Suppl):S469.","journal-title":"Value Health"},{"key":"1377_CR70","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2165\/00019053-200826090-00009","volume":"26","author":"M Sculpher","year":"2008","unstructured":"Sculpher M. Subgroups and heterogeneity in cost-effectiveness analysis. Pharmacoeconomics. 2008;26:799\u2013806. https:\/\/doi.org\/10.2165\/00019053-200826090-00009.","journal-title":"Pharmacoeconomics"},{"key":"1377_CR71","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1136\/bmj.328.7436.360","volume":"328","author":"M Ryan","year":"2004","unstructured":"Ryan M. Discrete choice experiments in health care. BMJ. 2004;328:360\u20131. https:\/\/doi.org\/10.1136\/bmj.328.7436.360.","journal-title":"BMJ"},{"key":"1377_CR72","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2165\/11590150-000000000-00000\/FIGURES\/TAB2","volume":"9","author":"A Richter","year":"2011","unstructured":"Richter A, Thieda P, Thaler K, Gartlehner G. The impact of inclusion criteria in health economic assessments. Appl Health Econ Health Policy. 2011;9:139\u201348. https:\/\/doi.org\/10.2165\/11590150-000000000-00000\/FIGURES\/TAB2.","journal-title":"Appl Health Econ Health Policy"},{"key":"1377_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_100028","volume":"41","author":"NB Leighl","year":"2021","unstructured":"Leighl NB, Nirmalakumar S, Ezeife DA, Gyawali B. An arm and a leg: the rising cost of cancer drugs and impact on access. Am Soc Clin Oncol Educ Book. 2021;41:1\u201312. https:\/\/doi.org\/10.1200\/EDBK_100028.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1377_CR74","unstructured":"NICE Technology appraisal data: cancer appraisal recommendations. Technology appraisal data. NICE"},{"key":"1377_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00705-7","volume":"23","author":"B Furlow","year":"2022","unstructured":"Furlow B. US cancer drug prices do not reflect benefits to patients. Lancet Oncol. 2022;23: e532. https:\/\/doi.org\/10.1016\/S1470-2045(22)00705-7.","journal-title":"Lancet Oncol"},{"key":"1377_CR76","unstructured":"NICE Semaglutide for managing overweight and obesity. Guidance [TA875]. Available at: https:\/\/www.nice.org.uk\/guidance\/ta875. Accessed 13 Mar 2024"},{"issue":"5","key":"1377_CR77","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1177\/0272989X15610780","volume":"36","author":"A Basu","year":"2015","unstructured":"Basu A, Carlson JJ, Veenstra DL. A framework for prioritizing research investments in precision medicine. Med Decis Making. 2015;36(5):567\u201380. https:\/\/doi.org\/10.1177\/0272989X15610780.","journal-title":"Med Decis Making"},{"key":"1377_CR78","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/S40273-022-01203-0","volume":"41","author":"NR Naylor","year":"2023","unstructured":"Naylor NR, Williams J, Green N, Lamrock F, Briggs A. Extensions of health economic evaluations in r for Microsoft excel users: a tutorial for incorporating heterogeneity and conducting value of information analyses. Pharmacoeconomics. 2023;41:21\u201332. https:\/\/doi.org\/10.1007\/S40273-022-01203-0.","journal-title":"Pharmacoeconomics"},{"issue":"56","key":"1377_CR79","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/S00125-013-2940-Y","volume":"2103","author":"AJ Hayes","year":"2013","unstructured":"Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia. 2013;2103(56):1925\u201333. https:\/\/doi.org\/10.1007\/S00125-013-2940-Y.","journal-title":"Diabetologia"},{"key":"1377_CR80","doi-asserted-by":"publisher","DOI":"10.1136\/BMJOPEN-2021-049675","volume":"11","author":"M Hoogendoorn","year":"2021","unstructured":"Hoogendoorn M, Corro Ramos I, Soulard S, Cook J, Soini E, Paulsson E, Rutten-Van M\u00f6lken M. Cost-effectiveness of the fixed-dose combination tiotropium\/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting \u03b22-agonist\/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study. BMJ Open. 2021;11: e049675. https:\/\/doi.org\/10.1136\/BMJOPEN-2021-049675.","journal-title":"BMJ Open"},{"key":"1377_CR81","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1177\/0272989X20932145","volume":"40","author":"I Corro Ramos","year":"2020","unstructured":"Corro Ramos I, Hoogendoorn M, Rutten-van M\u00f6lken MPMH. How to address uncertainty in health economic discrete-event simulation models: an illustration for chronic obstructive pulmonary disease. Med Decis Making. 2020;40:619\u201332. https:\/\/doi.org\/10.1177\/0272989X20932145.","journal-title":"Med Decis Making"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-024-01377-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-024-01377-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-024-01377-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T05:04:06Z","timestamp":1718427846000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-024-01377-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,27]]},"references-count":81,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1377"],"URL":"https:\/\/doi.org\/10.1007\/s40273-024-01377-9","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,27]]},"assertion":[{"value":"21 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors received no financial support for the research, authorship, or publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Gemma E. Shields, Paul Clarkson, Ash Bullement, Warren Stevens, Mark Wilberforce, Tracey Farragher, Arpana Verma and Linda M. Davies have no competing interests to declare that are relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research Involving Human Participants and\/or Animals"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualisation: GES, MW, PC, TF, AV and LMD. Screening: GES, AB, PC and MW. Data extraction: GES, AB, PC, MW and WS. Writing\u2014original draft preparation: GES. Writing\u2014review and editing: GES, MW, PC, TF, AV, AB, WS and LMD.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}